MAXIPIME
CEFEPIME HYDROCHLORIDE
Approval overview MAXIPIME is listed in Drugs@FDA under application 050679 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFEPIME HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOSPIRA INC Submission history Latest submission status date: 2021-08-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview MAXIPIME is listed in Drugs@FDA under application 050679 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFEPIME HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOSPIRA INC Submission history Latest submission status date: 2021-08-11 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.